Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: HerbertOtto who wrote (20640)	5/13/1998 4:57:00 AM
From: Henry Niman	Respond to of 32384

I think that SRGN's technology will get more exposure under LGND's management. ONTAK and topical Targretin both target CTCL and both are slated for a significant FDA action this year, but onlt Targretin appears on the Biotech hit list: Expected Notable Events in 1998 for Biotechnology Company Treatment/Product Anticipated Launches: CompanyProductIndication Advanced Tissue ScienceDermagraftDiabetic Skin Ulcers CephalonProvigilNarcolepsyCephalonMyotrophinAmyotrophic Lateral Sclerosis (Lou Gehrig) ChironRegranex/PDGF Diabetic foot ulcer - wound healing COR Therapeutics Integrelin Unstable Angina indication IDEC Pharmaceuticals Rituxan Monoclonal Antibody for B-Cell Lymphoma MedimmuneMEDI-493RSV Infection Molecular BiosystemsOptisonContrast agent for ultrasound imaging PathoGenesis TOBI Inhaled tobramycin for cystic fibrosis Protein Design Labs Zenapax Reduction of kidney transplant rejection SangStatCyclosporineReduction of organ transplant rejection SangStatThymoglobulinReduction of kidney transplant rejection Awaiting FDA Approval: CompanyProductIndication Centocor AvakineCrohn's Disease ChironPertugenAcellular Pertussis Vaccine GelTex RenaGel Chronic kidney failureImmunex ENBREL Rheumatoid arthritis Interneuron Citacoline Ischemic stroke Ligand Panretin Gel Kaposi's Sarcoma MedImmune MEDI-493 Monoclonal Ab for RSV disease NexStar AmbisomeFungal infections - empiric therapy North American Vaccine Cervita Acellular Pertussis Vaccine Sepracor R-albuterol Single isomer albuterol for asthma treatment Magainin CytolexInfections in diabetic foot ulcers Zonagen Vasomax Male impotence Phase III trials to be completed in 1998: CompanyProductIndication Amylin PramlintideDiabetes - improved glucose control Biochem Pharma Lamivudine Chronic hepatitis B infection British Biotech Lexipafant Acute pancreatitis Creative BioMoleculesOP-1 Bone graft substitute Genentech HerceptinMonoclonal Antibody for Breast Cancer Ligand Targretin Gel Cutaneous T-cell lymphoma NeurexSNX-111 Cancer and neuropathic pain OrganogenesisApligrafWound healing in diabetic ulcers SonusEcogenContrast agent for ultrasound imaging Vertex VX-478 2nd Generation Protease Inhibitor